Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): A trial of the Eastern Cooperative Oncology Group
Antineoplastic Combined Chemotherapy Protocols
Drug Resistance, Multiple
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasm Recurrence, Local
VAD plus PSC-833 had the same (21%) partial response rate as a prior ECOG study without PSC-833. No correlation of response with MDR or apoptosis testing was found. Other drug resistance factors must play a significant role in determining the response of relapsed patients with CLL.